Higher dose of tanezumab meets in latest Phase III pain readout

Pfizer and partner Eli Lilly reported on Feb. 19 that the 10 mg dose of tanezumab met the primary endpoint in the Phase III A4091059 trial to treat chronic low back pain.

The data follow a January readout in which

Read the full 392 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE